Analysts believe that Biogene's drug, which was called BG-12 in the clinical trial stage, will take a 20% market share worth $3.25 billion annually.
In 2012 Copaxone had annual sales of $4 billion, 19.7% of Teva's overall revenue, and was reportedly responsible for 40-60% of the pharmaceutical company's profit. Thus any harm to Copaxone's market standing raises investor concerns and pushes Teva's share price down.
Tecfidera is set to become the third oral multiple sclerosis treatment on the market after Novartis's Gilenya and Sanofi's Aubagio.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments